North Carolina GLP-1 Med Spa Compliance Rules 2026

A medical weight loss line is the fastest revenue most North Carolina med spas have ever added, and it converts a cosmetic practice into a chronic-disease practice overnight. The injector who was handling a fifteen-minute neurotoxin appointment now manages a titration schedule, a contraindication list carrying a boxed warning, and a patient under treatment for a year or more.

North Carolina makes this harder by being almost entirely silent: no medical spa statute, no weight loss clinic registration, no GLP-1 rule. Operators mistake that silence for freedom. It is the opposite — silence means the general rules apply in full, and they are unusually specific about who may prescribe and under what documented supervision. Three bodies matter: the North Carolina Medical Board (NCMB), governing physicians and physician assistants; the North Carolina Board of Nursing (NCBON), governing nurses and sharing jurisdiction over nurse practitioners; and the North Carolina Board of Pharmacy, governing where your drug comes from and whether you may hand a patient a vial at all.

This guide is North Carolina only. For the general mechanics — how GLP-1 programs work anywhere, the federal compounding architecture from first principles — read our national GLP-1 med spa compliance guide. Everything below asks one question: what does North Carolina add?

GLP-1 Prescribing Is the Practice of Medicine Here

Every question below resolves once you accept the classification. Selecting semaglutide for a patient, setting a dose, and writing the order is practising medicine, and the fact that the goal is weight rather than disease does not move it elsewhere.

What § 90-18 captures

N.C. Gen. Stat. § 90-18 provides that any person shall be regarded as practising medicine who shall diagnose, treat, or prescribe for or administer to any human ailment of another person. That phrasing does two jobs: "prescribe for" captures the clinician who evaluates the patient and selects the drug, "administer to" whoever injects it. Both are medicine, lawful only for someone whose licence reaches them or a qualified delegate. Obesity is a diagnosable condition and a GLP-1 carries a boxed warning for thyroid C-cell tumours; nothing here is cosmetic in the regulatory sense, whatever the marketing says.

No clinic licence, no GLP-1 rule, and where the state is silent

North Carolina does not license med spas or weight loss clinics as facilities and has adopted no rule specific to GLP-1 prescribing. What it does require is corporate: a professional corporation or PLLC formed to practise medicine must obtain a Certificate of Registration from the NCMB under Chapter 55B — an ownership filing, not a permit for a treatment menu, as our North Carolina regulations summary sets out.

Being candid about gaps beats inventing rules to fill them. There is no statutory definition of a good faith examination, no codified monitoring interval for weight management, no limit on how far apart a supervising physician and a supervised prescriber may sit, and no NCMB position statement on medical weight loss specifically. Where this guide says the state is silent, that is a finding — and silence never means the underlying prescribing and supervision rules stop applying.

Who May Prescribe a GLP-1 in North Carolina

The direct answer, with the condition that actually gets practices cited attached to each row.

There is no fourth prescriber

Every model that appears to add one — a nurse-run intake, a protocol pre-approving anyone over a BMI threshold, a remote physician signing orders in batches without forming a judgment about the individual — is the same violation wearing different clothes.

Nurse Practitioners: North Carolina Is Not a Full-Practice-Authority State

This is the most consequential fact for a North Carolina med spa, because the NP is the most common prescriber in this business model and operators arriving from a full-practice-authority state routinely get it wrong.

Dual-Board approval comes first

A North Carolina nurse practitioner is approved jointly by the NCMB and the NCBON, and the rules appear twice in the administrative code — 21 NCAC 32M under the Medical Board and 21 NCAC 36 .0800 under the Board of Nursing. Under 21 NCAC 32M .0104, an NP may not perform medical acts until notification of approval to practise has been received. An NP who starts writing GLP-1 prescriptions at a new site before that approval lands is outside the rule, and the physician who allowed it is exposed alongside them.

What the collaborative practice agreement must contain

Under 21 NCAC 32M .0110 and the parallel nursing rule 21 NCAC 36 .0810, the NP must hold a signed, dated collaborative practice agreement with a primary supervising physician, available at each practice site, reviewed at least yearly and acknowledged with a dated signature sheet signed by both, the two remaining continuously available to each other for consultation.

Two consequences follow, both routinely missed. The agreement is site-specific: a practice opening a second location has not automatically extended it. And the annual review is a documented event with two signatures, not a filing completed once at hire. An expired review sheet is the easiest finding an investigator can make, and it is the first document requested.

The agreement defines what the NP may prescribe

Under 21 NCAC 32M .0109, the drugs an NP may prescribe at each site are those included in the collaborative practice agreement. Many weight loss programs have a latent problem here: the NP holds a valid CPA written for the aesthetics side, and nobody amended it when the GLP-1 line launched. If semaglutide and tirzepatide fall outside the drug categories it describes, the NP's authority to prescribe them is at best arguable.

Worth noting: GLP-1 receptor agonists are not controlled substances, so the controlled-substance machinery in .0109 does not apply, and the DEA telemedicine rules are irrelevant here. Full practice authority legislation has been introduced repeatedly and has repeatedly failed, most recently in 2025. Any vendor telling you North Carolina NPs can now practise independently is describing a bill, not a law.

Physician Assistants: What Session Law 2025-37 Changed

The PA route is the one place North Carolina genuinely moved this year, and the change is narrower than the headlines suggested.

The signed supervisory arrangement

Under 21 NCAC 32S .0213, each supervising physician and PA signs a statement describing the supervisory arrangements in all settings, kept on file at every practice site, and the PA maintains written prescribing instructions at each site. The rule also requires meetings: monthly for the first six months of a new arrangement, then at least every six months, recorded and signed by both. Note what it does not require — physical presence. The documentation is the supervision: if the meeting records do not exist, it did not happen as far as the Board is concerned.

Team-based practice, and why most med spas will not qualify

House Bill 67, signed as Session Law 2025-37 on July 1, 2025, created a team-based practice pathway letting certain PAs practise without a primary supervising physician for the first time in state history, effective when the NCMB adopted implementing rules or on June 30, 2026, whichever came first. The conditions are strict: more than 4,000 hours of clinical experience as a licensed PA and more than 1,000 hours within the specialty. The setting must qualify too — majority-owned collectively by licensed physicians, with a North Carolina-licensed physician owner having consistent and meaningful participation in the design and implementation of health services, and physicians and team-based PAs working in the same clinical practice area.

Read that against a typical med spa. Majority physician ownership excludes the investor-owned models that dominate this industry, and "same clinical practice area" fits poorly where the owner is a dermatologist and the PA runs weight management. Most North Carolina med spas will not qualify. How the NCMB will apply "consistent and meaningful participation" to a cosmetic or weight-loss practice is genuinely unsettled; we would not build a staffing model on an optimistic reading before that is clearer.

The Good Faith Examination: Assembled, Not Codified

This is the requirement weight loss programs most often get wrong. No North Carolina statute or rule says "good faith exam," and some operators treat that as permission to skip the step. It is not: the requirement is assembled from § 90-18, which makes prescribing for a person the practice of medicine, and the NCMB's prescribing position statement, which sets out what the prescriber must do first.

What Position Statement 4.1.1 demands

NCMB Position Statement 4.1.1, Contact With Patients Before Prescribing — carried in the Board's compendium, updated January 2026 — states that prescribing drugs to an individual the prescriber has not examined to the extent necessary for an accurate diagnosis is inappropriate. The expectation is an appropriate history and physical examination, a working diagnosis, and a therapeutic plan. Prescribing based solely on answers to a set of questions does not meet it.

That describes, almost exactly, the intake model many weight loss programs run on. Position statements are interpretive rather than regulatory, but they establish the criteria Board staff use in investigations and settlements.

What the exam has to cover

North Carolina does not enumerate the elements, so this is clinical standard of care rather than a citable state rule. But a prescriber who cannot show the following will struggle to argue the exam was adequate: measured height, weight and BMI; the indication; personal or family history of medullary thyroid carcinoma or MEN 2; pancreatitis and gallbladder history; pregnancy status; current medications; and a documented discussion of alternatives, adverse effects and what happens when treatment stops. The consent form your program uses is no substitute: a signed consent proves the patient was told something, not that a prescriber evaluated them.

Telehealth: Permitted, and Not a Shortcut

Telehealth is where the North Carolina GLP-1 model lives or dies, because nearly every program uses it for at least the follow-ups.

The standard of care does not change with the modality

NCMB Position Statement 5.1.4, Telemedicine, holds that licensees treating North Carolina patients by telemedicine are held to the same established standard of care as those practising in person. That evaluation need not be in person if the technology is sufficient to accurately diagnose and treat in conformity with the applicable standard of care, and the statement points back to 4.1.1 for cases where an initial in-person evaluation is necessary.

So: yes, telehealth can satisfy the required evaluation in North Carolina — a real-time encounter with a prescriber who obtains what is needed to form a reasonably presumptive treatment plan. What it does not do is lower the bar. North Carolina has no comprehensive telemedicine statute setting a different prescribing standard; the standard comes from the Board.

The asynchronous questionnaire is the exposure

A store-and-forward intake with no live clinician contact sits directly in the space 4.1.1 describes as inappropriate. If your program's first patient contact is a form and the first human contact is the nurse who injects, you do not have a good faith exam — you have a document trail showing a prescription issued without one, and it is visible in your own software. Separately, a prescriber treating a patient located in North Carolina needs a North Carolina licence, wherever they sit; the Interstate Medical Licensure Compact changes how a physician obtains one, not whether one is needed.

What a Registered Nurse May and May Not Do

The RN is the operational centre of most weight loss programs and the role most often stretched past its scope, usually with nobody intending anything improper.

What the RN may do

An RN may administer semaglutide or tirzepatide pursuant to a valid, patient-specific order from a prescriber acting within their own legal scope. Administering prescribed medication is core registered nursing practice under N.C. Gen. Stat. § 90-171.20, which describes nursing as including the implementing of prescribed treatment. The RN may perform a nursing assessment, record vitals and weights, teach injection technique, and report findings — and does not need the prescriber physically present.

The NCBON's position statement on cosmetic and aesthetic dermatological procedures is the closest analogue the Board has published. A GLP-1 injection is ordinary medication administration rather than a cosmetic procedure, so it does not govern directly, but its conditions are the right template: documented training and demonstrated competency in the technique, and written policies covering the procedure and emergency response.

What the RN may not do

Section 90-171.20 is explicit that a nurse may not prescribe a medical treatment regimen or make a medical diagnosis. Four concrete prohibitions follow: an RN may not determine that a patient is a candidate, may not prescribe, may not independently escalate or reduce a dose — the most common real-world breach, because titration feels administrative and is not — and may not restart therapy after a hold without a new prescriber decision.

The fix is a titration schedule written by the prescriber specifying the dose at each interval and the parameters requiring prescriber contact first. A nurse following a prescriber-authored schedule is implementing prescribed treatment; a nurse deciding the next dose is prescribing. The difference lies entirely in whether the decision was made in advance, by the right person, for that patient — our GLP-1 monitoring schedule template and tirzepatide protocol guide set out what that document contains.

LPNs, medical assistants, and everyone else

An LPN may administer only under direct on-site supervision — a materially different staffing requirement that quietly determines whether a satellite location can open on a given day. Medical assistants are not licensed or registered at all in North Carolina, so an MA has no scope of practice to work from, and injecting a prescription drug is not a task any North Carolina authority has approved for delegation to unlicensed personnel. The reasoning that keeps an MA away from a syringe of neurotoxin, set out in our North Carolina Botox injector guide, keeps them away from a GLP-1.

What the Medical Director Actually Owes

North Carolina issues no med spa facility licence and no statute uses the phrase "medical director" for a med spa, so the title carries no legal weight. The duties behind it are real, because every non-physician prescriber draws authority from a physician.

The competence precondition

NCMB Position Statement 9.1.1, Physician Supervision of Other Licensed Health Care Professionals, contains the condition that catches paper directors: a physician should supervise only those procedures and that care in which the physician is trained and competent. A dermatologist who has never managed obesity pharmacotherapy, supervising an NP running a GLP-1 line, is outside that statement however carefully the collaborative practice agreement is drafted. It is the question we would expect the Board to ask first.

Supervision is a file, not a state of mind

For a GLP-1 program that file holds the collaborative practice agreement or supervisory arrangement naming this physician and this prescriber at this site; the annual CPA review sheet signed and dated inside the last twelve months; PA meeting records where a PA is involved; drug categories in the CPA that actually cover GLP-1 therapy; the written titration and monitoring protocol; competency documentation for everyone who administers; and the emergency response policy. Our medical director guide covers what cannot be delegated. What the title does not buy: it does not cure an inadequate exam, authorise an RN to titrate, or transfer liability away from the licensee who made the clinical decision.

Charting and Monitoring: What the Record Has to Show

North Carolina sets no minimum visit interval for weight management and prescribes no chart template. That absence is exactly why the record matters: with no safe harbour to point at, the chart is the only evidence the standard of care was met.

Baseline and titration

Before the first dose the chart should carry the prescriber's own evaluation and identity, the exam elements above, contraindications screened and named individually rather than as a blanket "none," the consent discussion, and the treatment plan with its titration schedule and stopping criteria. Each escalation should then be traceable to a prescriber decision, or to a schedule that anticipated it, with the tolerance assessment that supported proceeding. The failure mode we see repeatedly is a chart recording doses administered but never who decided the dose should rise — a gap that converts a nursing task into an allegation of unlicensed prescribing, and one that is invisible until someone asks.

Adverse events and discontinuation

Document nausea, vomiting and dehydration; any suspected pancreatitis or gallbladder event and the referral that followed; every hold and its reason; and the discontinuation conversation, including what the patient was told about weight regain. Programs are far better at recording the sale than the stop, and a practice that cannot show what it did when a patient reported severe abdominal pain has a problem no protocol binder fixes afterwards.

Compounded Semaglutide and Tirzepatide: Where the Federal Position Stands

This has moved more than any other part of the picture, and repeating a 2024 answer in 2026 is the commonest way a North Carolina practice falls out of compliance without noticing. North Carolina adds no state-specific GLP-1 compounding rule; the constraint is federal, and it is now tight.

The shortage route is closed

Compounding these drugs at scale was lawful because they sat on the FDA's drug shortage list. That is over. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, and enforcement deadlines followed: 503A pharmacies had to stop compounding tirzepatide by February 18, 2025 and 503B outsourcing facilities by March 19, 2025; for semaglutide the dates were April 22, 2025 and May 22, 2025. The Outsourcing Facilities Association failed to obtain a preliminary injunction against the FDA in April 2025.

What 503A can still do, and how narrow it is

Patient-specific compounding under section 503A has not disappeared, but it is far narrower than the shortage-era market. A 503A pharmacy may not compound a drug that is essentially a copy of a commercially available product. The exception requires the prescribing practitioner to determine and document that the compounded version produces a clinically significant difference for that individual patient — and the FDA has been clear this cannot be boilerplate applied across a panel.

The semaglutide-plus-B12 formulation that became the standard workaround does not escape the analysis. The FDA's position is that such a combination is still essentially a copy where the route of administration matches and the active ingredient amount is within ten per cent of the approved product's strength, and that a justification like "weight management with B12 supplementation" fails because the patient could take the approved product and the B12 separately. If your pharmacy's clinical-difference language is identical on every prescription, it is not doing the work you think it is. Our 503A versus 503B sourcing guide works this through in detail.

503B and the April 2026 bulks-list proposal

A 503B outsourcing facility may compound from a bulk drug substance only if that substance is on the FDA's 503B bulks list or the shortage list. Semaglutide and tirzepatide are on neither. On April 30, 2026 the FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, publishing the notice in the Federal Register on May 1, 2026, finding no clinical need and expressly rejecting affordability and insurance access as constituting it. The comment period closed on July 30, 2026.

Be precise about status: that proposal is not yet final. The FDA has issued no final determination and committed to no timeline. But today's position does not depend on the outcome — with no shortage listing and no bulks listing, large-scale 503B compounding of these drugs is already impermissible. A final exclusion would close the door rather than move it.

The personal-use and "research use only" traps

Two sourcing routes are marketed hard to med spas and both are indefensible. The first is peptide vials sold as "research use only" or "not for human use." Those products are not manufactured, tested or labelled for administration to people, and the labelling is not a shield — it is an admission the seller knows the product is not approved for the use you intend. The FDA has stated there is no lawful basis for compounding peptide salt forms such as semaglutide sodium or acetate, and importing active pharmaceutical ingredient through research-chemical channels is unlawful regardless of shortage status.

The second is personal importation. That narrow FDA posture concerns individuals obtaining medication for their own use; it has never authorised a clinic to stock foreign or unapproved product for administration to patients. A practice buying from an overseas supplier is holding unapproved drug for commercial administration — a federal problem and, derivatively, an NCMB and Board of Pharmacy problem. Both routes also void the ordinary liability position, since most carriers exclude administration of unapproved products.

Sourcing, Dispensing, and the Board of Pharmacy

This is the section most North Carolina med spas have never read, and it contains a live registration requirement many weight loss programs are currently in breach of without knowing it.

Office stock versus dispensing

Under the Board of Pharmacy's compounding rule at 21 NCAC 46 .2801, a pharmacy may supply compounded drug products to practitioners authorised by law to prescribe, for those practitioners to administer to their own patients — the office-use pathway supporting stock in the fridge for in-clinic injection. The same rule provides that a pharmacy may dispense a compounded preparation to a patient only pursuant to a valid prescription for that individual patient, and requires three years of preparation records plus compliance with USP chapters <795> and <797>. The line is administration versus dispensing: injecting a dose in your treatment room is administration, handing the patient a vial to take home is dispensing — a regulated activity with its own permissions.

The dispensing physician registration nobody files

Under N.C. Gen. Stat. § 90-85.21(b), a physician who dispenses prescription drugs for a fee or other charge must register annually with the North Carolina Board of Pharmacy as a dispensing physician, and comply in all respects with the laws and rules governing pharmacy practice — drug utilisation review, counselling, packaging, labelling and record keeping. Authority to discipline a physician who fails to comply sits with that physician's own licensing board, which makes an unregistered arrangement an NCMB matter, not merely a pharmacy one. Any med spa selling take-home vials at a per-vial or bundled price should assume it is dispensing for a fee. Usually the registration does not exist.

Dispensing PAs and nurse practitioners

The rule for non-physician prescribers is stricter, and closes off the arrangement most med spas would reach for. A dispensing PA or NP must register with the Board of Pharmacy before any dispensing activity, and may only dispense from a place holding a North Carolina pharmacy permit. They may not register as independent dispensers, nor dispense under a dispensing physician's supervision. Translated: a med spa without a pharmacy permit cannot have its NP or PA dispensing take-home vials at all. The compliant models are in-clinic administration from lawfully obtained office stock, or a patient-specific prescription sent to a licensed pharmacy that dispenses to the patient.

Advertising Claims and the File a Complaint Produces

Two exposures remain, and they are the two that most often start an investigation rather than end it.

What NCMB says about advertising

NCMB Position Statement 8.3.1, Advertising and Publicity, holds that advertising which is deceptive, false or misleading constitutes unprofessional conduct under the Medical Practice Act, and defines advertising broadly enough to cover oral, written and digital communication disseminated by or at a licensee's direction. Its principles are direct: no false claims or misrepresentations of fact either expressly or by implication, no omission of material facts, and licensees should be prepared to substantiate what they claim. Unprofessional conduct is a ground for discipline under N.C. Gen. Stat. § 90-14.

"By implication" and "omit material facts" are the operative phrases for weight loss marketing: a before-and-after gallery with no disclosure that results are not typical, a guaranteed pound-per-week figure, "medically supervised" copy for a program whose physician has never met a patient, and the routine failure to say that a product is compounded rather than the FDA-approved brand.

The federal overlay is active

The FDA has run three enforcement waves against telehealth and compounding marketing in about a year: roughly eighty warning letters in September 2025, thirty on March 3, 2026, and twenty-five more on June 16, 2026. The claims cited are the ones weight loss programs make casually — that a compounded product is equivalent in safety and quality to the branded drug, contains "the same active ingredient as Wegovy," or is a "generic" alternative. There is no approved generic semaglutide, and saying otherwise in an ad is a federal misbranding problem and an 8.3.1 problem at once.

The documentation a complaint produces

A complaint — usually about an adverse effect, a refund, or a result that never arrived — produces a document request. It is the supervision file described above, plus three things that file does not hold: source documentation for the product administered, including the pharmacy, its 503A or 503B status, the lot number and any clinical-difference determination; the signed consent; and the advertising the patient saw. Assemble it now, while it is a filing exercise — assembling it after a complaint is when practices discover which piece never existed. If you would rather not build the underlying protocols, consents and monitoring templates from scratch, our library of med spa SOP and protocol templates covers the documentation behind every step above.

North Carolina GLP-1 compliance in plain terms

• Prescribing for or administering to a person is the practice of medicine under § 90-18.
• Only physicians, PAs and approved NPs may prescribe a GLP-1 here.
• North Carolina is not a full practice authority state; the NP collaborative practice agreement is mandatory (21 NCAC 32M .0110).
• The CPA defines which drugs the NP may prescribe (21 NCAC 32M .0109) — check that it covers GLP-1s.
• No statute says "good faith exam," but NCMB Position Statement 4.1.1 supplies the substance.
• Telehealth is held to the same standard of care (Position Statement 5.1.4); a questionnaire alone is not.
• RNs administer on a valid order; § 90-171.20 bars nurses from diagnosing or prescribing a treatment regimen.
• No shortage-based compounding route has existed since 2025; the FDA's April 2026 bulks-list proposal is not yet final.
• Take-home vials for a fee are dispensing, triggering Board of Pharmacy registration under § 90-85.21(b).

For more North Carolina-specific compliance guides as this cluster grows, browse the North Carolina med spa compliance hub.

This article is for informational purposes only and does not constitute legal or medical advice. North Carolina prescribing, supervision and delegation requirements are administered by several bodies — the North Carolina Medical Board, the North Carolina Board of Nursing and the North Carolina Board of Pharmacy — and they change over time, as do the federal compounding rules described here, which remain subject to a pending FDA determination. Where North Carolina is silent or its position is genuinely unsettled, we have said so rather than guessed. Confirm current requirements with the relevant board and consult a North Carolina healthcare attorney before making staffing, sourcing or program design decisions.

Frequently Asked Questions